Sanofi SA (SASY.PA)
76.85EUR
11:36am EDT
€-3.32 (-4.14%)
€80.17
€75.75
€77.10
€74.80
7,272,693
2,671,559
€87.03
€64.20
About
Overall
| Beta: | 0.48 |
| Market Cap (Mil.): | €107,297.90 |
| Shares Outstanding (Mil.): | 1,338.20 |
| Dividend: | 2.77 |
| Yield (%): | 3.46 |
Financials
| SASY.PA | Industry | Sector | |
|---|---|---|---|
| P/E (TTM): | 25.54 | 37.93 | 37.76 |
| EPS (TTM): | 3.14 | -- | -- |
| ROI: | -- | 19.48 | 18.76 |
| ROE: | -- | 20.17 | 19.59 |
Sanofi cuts 2013 goal, authorities visit China office
PARIS - Sanofi SA cut its 2013 earnings forecast as it reported a steeper-than-expected drop in second-quarter profit, hit by the effect of patent losses, currency fluctuations and an inventory setback in Brazil.
UPDATE 2-Sanofi cuts 2013 goal, authorities visit China office
* Shares down 6.2 percent (Adds details, CEO comments, background)
BRIEF-Sanofi opens 5.8 pct lower on Q2, 2013 target cut
PARIS, Aug 1 - Sanofi SA : * opens 5.8 percent lower on Q2 earnings miss, 2013 target cut, China probe
Sanofi CEO says authorities visit China office
PARIS - Sanofi said one of its regional offices in China has been visited by the State Administration for Industry and Commerce in Shenyang as part of a probe into a bribery scandal that has involved other Western drugmakers.
Sanofi CEO says authorities visit China office
PARIS, Aug 1 - Sanofi said one of its regional offices in China has been visited by the State Administration for Industry and Commerce in Shenyang as part of a probe into a bribery scandal that has involved other Western drugmakers.
FDA panel recommends over-the-counter use of Sanofi allergy drug
WASHINGTON - Sanofi SA's allergy drug Nasacort AQ is safe enough to be used without a prescription, a panel of advisors to the U.S. Food and Drug Administration ruled on Wednesday.
FDA panel recommends over-the-counter use of Sanofi allergy drug
WASHINGTON, July 31 - Sanofi SA's allergy drug Nasacort AQ is safe enough to be used without a prescription, a panel of advisors to the U.S. Food and Drug Administration ruled on Wednesday.
UPDATE 1-Sanofi allergy drug safe for non-prescription use-FDA reviewers
WASHINGTON, July 29 - Sanofi SA's allergy drug Nasacort AQ is safe enough to be used without a prescription, according to reviewers for the U.S. Food and Drug Administration.
Sanofi allergy drug safe enough for non-prescription use -FDA reviewers
WASHINGTON, July 29 - Sanofi SA's allergy drug Nasacort AQ is safe enough to be sold over the counter, according to reviewers for the U.S. Food and Drug Administration.
Sanofi, Carlyle in talks to buy Elder Pharma's India formulations business-sources
July 24 - Sanofi SA's India unit and Carlyle Group are in separate talks to buy the domestic drug formulations business of India's Elder Pharmaceuticals Ltd for $400 million-$450 million, three sources with direct knowledge of the matter said.
Earnings vs.
Estimates
Analyst Research Reports
| Report Title | Price |
|---|---|
|
Trading Report for (SNY). A detailed report, including free correlated market analysis, and updates.
Provider: Stock Traders Daily
|
$58.00
|
|
Provider: ValuEngine, Inc.
|
$25.00
|
|
Provider: Stock Traders Daily
|
$495.00
|
|
Provider: Finlabo SIM Spa
|
$10.00
|
|
Provider: S&P Capital IQ – STARS Reports
|
$127.00
|
NYSE and AMEX quotes delayed by at least 20 minutes. NASDAQ delayed by at least 15 minutes. For a complete list of exchanges and delays, please click here.

